Report Information More information from: https ://www.wis eguyreports .com/reports /495870
Anaplastic Astrocytoma - Pipeline Review, H1 2016 Report / Search Code: WGR495870
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
Anaplas tic As trocytoma - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Anaplas tic As trocytoma - Pipeline Review, H1 2016’, provides an overview of the Anaplas tic As trocytoma pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Anaplas tic As trocytoma, complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Anaplas tic As trocytoma and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of Anaplas tic As trocytoma - The report reviews pipeline therapeutics for Anaplas tic As trocytoma by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Anaplas tic As trocytoma therapeutics and enlis ts all their major and minor projects - The report as s es s es Anaplas tic As trocytoma therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Anaplas tic As trocytoma Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Anaplas tic As trocytoma - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics
- Devis e corrective meas ures for pipeline projects by unders tanding Anaplas tic As trocytoma pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Lis t of Tables 6 Lis t of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Anaplas tic As trocytoma Overview 9 Therapeutics Development 10 Pipeline Products for Anaplas tic As trocytoma - Overview 10 Pipeline Products for Anaplas tic As trocytoma - Comparative Analys is 11 Anaplas tic As trocytoma - Therapeutics under Development by Companies 12 Anaplas tic As trocytoma - Therapeutics under Inves tigation by Univers ities /Ins titutes 13 Anaplas tic As trocytoma - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Anaplas tic As trocytoma - Products under Development by Companies 16 Anaplas tic As trocytoma - Products under Inves tigation by Univers ities /Ins titutes 17 Anaplas tic As trocytoma - Companies Involved in Therapeutics Development 18 Aduro BioTech, Inc. 18 Axelar AB 19 Boehringer Ingelheim GmbH 20 Burzyns ki Res earch Ins titute, Inc. 21 Cavion LLC 22 Celldex Therapeutics , Inc. 23 e-Therapeutics Plc 24 Medicenna Therapeutics , Inc. 25 Millennium Pharmaceuticals , Inc. 26 Novartis AG 27 Orbus Therapeutics , Inc. 28 Pfizer Inc. 29 Tocagen Inc. 30 TVAX Biomedical, Inc. 31 Anaplas tic As trocytoma - Therapeutics As s es s ment 32 As s es s ment by Monotherapy Products 32 As s es s ment by Combination Products 33 As s es s ment by Target 34 As s es s ment by Mechanis m of Action 36 As s es s ment by Route of Adminis tration 38 As s es s ment by Molecule Type 40 Drug Profiles 42 ADU-623 - Drug Profile 42 Product Des cription 42 Mechanis m of Action 42 R& D Progres s 42 afatinib dimaleate - Drug Profile 43 Product Des cription 43 Mechanis m of Action 43 R& D Progres s 43 alis ertib - Drug Profile 48 Product Des cription 48 Mechanis m of Action 48 R& D Progres s 48 Antineoplas ton Therapy - Drug Profile 53 Product Des cription 53 Mechanis m of Action 53 R& D Progres s 53 AXL-1717 - Drug Profile 55 Product Des cription 55 Mechanis m of Action 55 R& D Progres s 55 CDX-1401 - Drug Profile 57 Product Des cription 57 Mechanis m of Action 57 R& D Progres s 57 Cellular Immunotherapy for Brain Tumors - Drug Profile 59 Product Des cription 59 Mechanis m of Action 59 R& D Progres s 59
Cellular Immunotherapy for Gliomas - Drug Profile 60 Product Des cription 60 Mechanis m of Action 60 R& D Progres s 60 Cellular Immunotherapy for Oncology - Drug Profile 61 Product Des cription 61 Mechanis m of Action 61 R& D Progres s 61 DNX-2401 - Drug Profile 63 Product Des cription 63 Mechanis m of Action 63 R& D Progres s 63 eflornithine hydrochloride - Drug Profile 66 Product Des cription 66 Mechanis m of Action 66 R& D Progres s 66 ETS-2101 - Drug Profile 67 Product Des cription 67 Mechanis m of Action 67 R& D Progres s 67 flucytos ine + TBio-01 - Drug Profile 69 Product Des cription 69 Mechanis m of Action 69 R& D Progres s 69 flucytos ine ER + vocimagene amiretrorepvec - Drug Profile 71 Product Des cription 71 Mechanis m of Action 71 R& D Progres s 71 irinotecan hydrochloride + TBio-02 - Drug Profile 74 Product Des cription 74 Mechanis m of Action 74 R& D Progres s 74 MDNA-55 - Drug Profile 76 Product Des cription 76 Mechanis m of Action 76 R& D Progres s 76 mibefradil dihydrochloride - Drug Profile 77 Product Des cription 77 Mechanis m of Action 77 R& D Progres s 77 nilotinib - Drug Profile 79 Product Des cription 79 Mechanis m of Action 79 R& D Progres s 79 Oncolytic Virus to Target IL-12 for Oncology - Drug Profile 83 Product Des cription 83 Mechanis m of Action 83 R& D Progres s 83 p28 - Drug Profile 84 Product Des cription 84 Mechanis m of Action 84 R& D Progres s 84 palbociclib - Drug Profile 86 Product Des cription 86 Mechanis m of Action 86 R& D Progres s 86 TVI-Brain-1 - Drug Profile 91 Product Des cription 91 Mechanis m of Action 91 R& D Progres s 91 Anaplas tic As trocytoma - Recent Pipeline Updates 93 Anaplas tic As trocytoma - Dormant Projects 127 Anaplas tic As trocytoma - Dis continued Products 128 Anaplas tic As trocytoma - Product Development Miles tones 129 Featured News & Pres s Releas es 129 Dec 07, 2015: Burzyns ki Res earch Ins titute Announces Favorable Objective Res pons e Rates and Overall Survival in Adults with Anaplas tic As trocytoma Following Antineoplas tons A-10 and AS2-1 129 Jun 18, 2015: Burzyns ki Res earch Ins titute Announces Publication of Phas e II Res ults in Adults with Recurrent Anaplas tic As trocytoma 129 Appendix 130 Methodology 130 Coverage 130 Secondary Res earch 130 Primary Res earch 130 Expert Panel Validation 130 Contact Us 130 Dis claimer 131
Lis t of Tables Number of Products under Development for Anaplas tic As trocytoma, H1 2016 10 Number of Products under Development for Anaplas tic As trocytoma - Comparative Analys is , H1 2016 11 Number of Products under Development by Companies , H1 2016 12 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 13 Comparative Analys is by Late Stage Development, H1 2016 14 Comparative Analys is by Clinical Stage Development, H1 2016 15 Products under Development by Companies , H1 2016 16 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 17 Anaplas tic As trocytoma - Pipeline by Aduro BioTech, Inc., H1 2016 18 Anaplas tic As trocytoma - Pipeline by Axelar AB, H1 2016 19 Anaplas tic As trocytoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 20 Anaplas tic As trocytoma - Pipeline by Burzyns ki Res earch Ins titute, Inc., H1 2016 21 Anaplas tic As trocytoma - Pipeline by Cavion LLC, H1 2016 22 Anaplas tic As trocytoma - Pipeline by Celldex Therapeutics , Inc., H1 2016 23 Anaplas tic As trocytoma - Pipeline by e-Therapeutics Plc, H1 2016 24 Anaplas tic As trocytoma - Pipeline by Medicenna Therapeutics , Inc., H1 2016 25 Anaplas tic As trocytoma - Pipeline by Millennium Pharmaceuticals , Inc., H1 2016 26 Anaplas tic As trocytoma - Pipeline by Novartis AG, H1 2016 27 Anaplas tic As trocytoma - Pipeline by Orbus Therapeutics , Inc., H1 2016 28 Anaplas tic As trocytoma - Pipeline by PďŹ zer Inc., H1 2016 29 Anaplas tic As trocytoma - Pipeline by Tocagen Inc., H1 2016 30 Anaplas tic As trocytoma - Pipeline by TVAX Biomedical, Inc., H1 2016 31 As s es s ment by Monotherapy Products , H1 2016 32 As s es s ment by Combination Products , H1 2016 33 Number of Products by Stage and Target, H1 2016 35 Number of Products by Stage and Mechanis m of Action, H1 2016 37 Number of Products by Stage and Route of Adminis tration, H1 2016 39 Number of Products by Stage and Molecule Type, H1 2016 41 Anaplas tic As trocytoma Therapeutics - Recent Pipeline Updates , H1 2016 93 Anaplas tic As trocytoma - Dormant Projects , H1 2016 127 Anaplas tic As trocytoma - Dis continued Products , H1 2016 128 Lis t of Figures Number of Products under Development for Anaplas tic As trocytoma, H1 2016 10 Number of Products under Development for Anaplas tic As trocytoma - Comparative Analys is , H1 2016 11 Number of Products under Development by Companies , H1 2016 12 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 13 Comparative Analys is by Clinical Stage Development, H1 2016 15 As s es s ment by Monotherapy Products , H1 2016 32 As s es s ment by Combination Products , H1 2016 33 Number of Products by Top 10 Targets , H1 2016 34 Number of Products by Stage and Top 10 Targets , H1 2016 34 Number of Products by Top 10 Mechanis m of Actions , H1 2016 36 Number of Products by Stage and Top 10 Mechanis m of Actions , H1 2016 36 Number of Products by Routes of Adminis tration, H1 2016 38 Number of Products by Stage and Routes of Adminis tration, H1 2016 38 Number of Products by Molecule Types , H1 2016 40 Number of Products by Stage and Molecule Types , H1 2016 40
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349